10 Apr 2026: B8F.DE Biofrontera AG XETRA pre-market rises to €6.80 on heavy volume

B8F.DE stock opened pre-market at €0.37 and climbed to €6.80 on heavy trade on 10 Apr 2026. The move shows a dramatic intraday swing versus the previous close of €0.32 and average volume of 605 shares. Volume at 45,797 shares gives a relative volume of 75.70, flagging outsized interest ahead of the XETRA session. Traders should note this is a high-volume mover in the Healthcare sector, and we connect the quote data to valuation and risk metrics below.

Pre-market move and volume: B8F.DE stock price action

B8F.DE stock registered a price range from €0.30 to €6.80 in pre-market prints on 10 Apr 2026. This represents a +2,000.00% reported change versus the prior close of €0.32. The spike accompanied 45,797 shares traded, far above the average volume of 605 shares. Such volume and gap moves often reflect corporate news, low free float dynamics, or order imbalances. Check company releases and exchange notices before trading.

Quote and valuation snapshot for B8F.DE stock

Key quote metrics: market cap €20,673,478.00, shares outstanding 3,038,430, and EPS -0.21. Price-to-sales stands at 0.64 and reported PE reads -32.40, reflecting negative earnings. Book value per share is €0.31, while price averages sit at €6.53 (50-day) and €9.19 (200-day). These ratios show a small-cap biotech with a high price-to-book gap and thin capitalization relative to its price move.

Financial health and operating metrics for B8F.DE stock

Trailing metrics show revenue per share €0.51 and net income per share -€0.01. Free cash flow per share is negative at -€0.04, and cash per share is €0.05. The current ratio of 1.76 suggests short-term coverage. Research and development equals 24.33% of revenue, consistent with a product-focused biopharma. Interest coverage remains strong at 318.80, reflecting minimal interest-bearing debt.

Technical liquidity and trading context for B8F.DE stock

Relative volume of 75.70 shows extraordinary interest versus the stock’s history. Average daily volume sits at 605 shares, so large trades will move the price. The very low float and a year low of €0.30 and year high of €22.58 create wide volatility. Traders should monitor order book depth on XETRA and use limit orders to manage execution risk.

Meyka rating and analyst positioning for B8F.DE stock

Meyka AI rates B8F.DE with a score of 58.77 out of 100 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. The score balances strong margins and low debt with negative EPS and thin market cap. This rating is informational and not individualized advice.

Risks, catalysts and sector comparison for B8F.DE stock

Key risks include small market cap €20.67m, volatile trading, and negative earnings. Catalysts could be regulatory approvals or U.S. sales updates for Ameluz. Healthcare sector averages show an average PE of 29.22, making Biofrontera’s negative PE a divergence. Low liquidity increases execution risk, while product launches represent upside potential.

Final Thoughts

B8F.DE stock is a high-volume mover in the XETRA pre-market on 10 Apr 2026, rising to €6.80 with 45,797 shares traded. The move contrasts with thin average liquidity of 605 shares and highlights execution and volatility risk. Meyka AI’s forecast model projects a one-year price target of €9.00, implying an upside of 32.27% versus the current price of €6.80. This forecast is model-based and not a guarantee. Investors should weigh the upside against negative EPS of -0.21, tight market cap €20,673,478.00, and sector peers. For trading, use limit orders and monitor company releases on the Biofrontera site and XETRA notices. Meyka AI provides this as AI-powered market analysis, not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.